SCHEMBL6326947

SCHEMBL6326947

Cc1ccc2nc(NC(CN3CCC(Cc4ccc(Cl)c(Cl)c4)CC3)C(C)C)oc2c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 5/20 0.57
SSTR5 P35346 3/20 0.39
FPR2 P25090 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37
FBP1 P09467 1/20 0.37
HRH1 P35367 1/20 0.36
HTR2B P41595 1/20 0.36
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
KCNH2 Q12809 1/20 0.35
AURKB Q96GD4 2/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
CHRNA7 P36544 1/20 0.35
HTR3A P46098 1/20 0.35
CTSL P07711 1/20 0.34
CTSS P25774 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326943 1.00 CCR3 (0.57) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6326938 1.00 CCR3 (0.57) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6325871 0.93 CCR3 (0.57) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6325867 0.93 CCR3 (0.57) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6325876 0.93 CCR3 (0.57) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6326066 0.92 CCR3 (0.51) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6326070 0.92 CCR3 (0.51) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6326064 0.92 CCR3 (0.51) CCR3SSTR5FPR2PROKR1FBP1
SCHEMBL6325973 0.90 CCR3 (0.54) CCR3SSTR5FPR2PROKR1HRH1
SCHEMBL6325978 0.90 CCR3 (0.54) CCR3SSTR5FPR2PROKR1HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090504-A1 Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists ROCHE PALO ALTO LLC 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090504-A1 Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists CCR9, CCR3, CCR1 CCR3 2/4885SSTR5 908/4885FPR2 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.